Asep Inc. Signs Letter of Intent for Joint Venture with Bahrain-based Seaspring W.L.L. for Regulatory Approval and Commercialization of Sepsis Diagnosis Technology in the Kingdom of Bahrain, the Middle East and North Africa – Yahoo Finance

VANCOUVER, BC, Jan. 6, 2023 /CNW/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is delighted to announce the recent signing of a Letter of Intent (LOI) for a joint venture between Asep Inc. and Seaspring W.L.L. (Seaspring), a Bahrain-based international investment consultancy firm. The joint venture will be owned 50/50 between Asep Inc. and Seaspring pursuant to a definitive agreement.
As per the terms of the LOI that was signed by both parties on December 11, 2022 in Bahrain, Seaspring will contribute the capital required by the joint venture to conduct its business operations while Asep Inc. will provide the licensing rights for use of the technology in the Kingdom of Bahrain and the Middle East and North Africa (MENA) region.
This critical milestone underscores Asep Inc.’s status as a global biotechnology company and its focus on mitigating antibiotic resistance and combatting sepsis, which causes 11 million deaths worldwide yearly.
Commenting on the occasion, Shaikh Isa bin Khalid Al-Khalifa, Founder and Managing Director of Seaspring, said, “I am extremely delighted to partner with Asep Medical Holdings Inc. to bring their exclusive medical diagnosis solutions to the Kingdom of Bahrain. With the introduction of Asep Inc.’s novel sepsis diagnostic technologies in Bahrain, we look forward to supporting and advancing the healthcare system in the country and that of the wider region. This marks an important step in Seaspring’s vision to facilitate the delivery of distinctive and sustainable solutions across vital sectors.”
Asep Inc.’s board member, Dr. Richard Heinzl, who facilitated the arrangement commented, “I am extremely impressed with the medical community in Bahrain, and under Sheikh Isa’s leadership, I see great potential for our ground-breaking sepsis technology in the region.”
Asep Inc.’s CEO, Dr. Robert E. W. Hancock stated “We are honoured to have attracted such a prestigious partner for a joint venture that will promote the successful launch of our products in a new region of the world, enabling us to address unmet medical needs. We consider this to be a tremendous endorsement of Asep’s leading edge technology that utilizes novel approaches to dealing with antibiotic failure, which is responsible for 20% of all deaths worldwide.”
ABOUT SEASPRING
Seaspring (seaspringconsulting.com) is a Bahrain-based international investment consultancy firm with a strategic focus on bringing distinct investment solutions from various sectors including, but not limited to healthcare, biotech, technology, and cybersecurity to the Gulf region.  Through key ties in the USA and Canada, Seaspring’s exclusive list of partners provide on the ground, strategically aligned, and lucrative investment options with a broad industry focus that cater to clients’ specific investment criteria.
ABOUT ASEP MEDICAL HOLDINGS INC.
Asep Medical Inc. (asepmedical.com) is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.
Sepset Biosciences Inc. (sepset.ca) is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure, since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The Sepset^ER test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 60-90 minutes of initiating the test, while other diagnostics provide a diagnosis after ~15 hours but can be as long as five days. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.
ABT Innovations Inc.’s (abtinnovations.ca) peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ear-nose and throat, sinusitis, orthopaedic, etc.), anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants.
FORWARD-LOOKING STATEMENTS —
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed,” “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements include but are not limited to the successful clinical testing of our Sepsis diagnostic test and its intended filing for regulatory approval; the Company not receiving regulatory approval as planned or at all; the undertaking of pre-clinical studies on our lead therapeutic, with the expectation that this will lead to fast-track clinical trials; the timeframe for diagnosis of sepsis with the company’s products; the potential opportunities for generation of revenue; the therapeutic benefits of the company’s products; and other statements regarding the company’s proposed business plans. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks including the risk that the company’s products may not perform as expected; that the company may not receive the requisite regulatory approvals or results of testing; the Company’s testing of the products may not be successful and approvals may not be obtained in the estimated timelines or at all;  the company may not be able to generate revenue from its products as expected or at all; the market for the company’s products may not be as described in this news release; and various other risk factors identified in the Asep Medical Inc.’s prospectus dated November 9, 2021, and in the company’s management discussion and analysis, available for review under the Company’s profile at www.sedar.com and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/asep-inc-signs-letter-of-intent-for-joint-venture-with-bahrain-based-seaspring-wll-for-regulatory-approval-and-commercialization-of-sepsis-diagnosis-technology-in-the-kingdom-of-bahrain-the-middle-east-and-north-africa-301715790.html
SOURCE ASEP Medical Holdings Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2023/06/c0737.html
Related Quotes
Inflation made the headlines through most of last year, for all the worst reasons: it ran far too high, peaked above 9% in June, and the inflationary pressures pushed down hard on stock markets. The Fed jacked interest rates up their highest level in over a decade, risking recession to fight the rise in prices. Today, inflation is still in the headlines, although the tone has shifted. The annualized rate is trending downward; the December number came in at 6.5% year-over-year. While this is good
Johns Hopkins University professor of applied economics Steve Hanke shares his outlook on the upcoming Federal Open Market Committee decision on interest rates and the current state of the money supply.
Adani and his companies are facing accusations of fraud from a New York short-seller, threatening the group's shares and his fortune.
Yahoo Finance Live’s Rachelle Akuffo discusses the decline in stock for Alibaba following rumors that the e-commerce company is moving its headquarters to Singapore, despite the company denying reports.
The legendary investor remains highly bearish. And for good reason.
MARKET PULSE Shares of United Parcel Service Inc. (UPS) sank $2.5 in premarket trading Tuesday, after the package delivery giant reported fourth-quarter profit that topped expectations but revenue that surprisingly declined, and provided a downbeat full-year outlook.
Costco has a tremendously loyal customer base with an over 90% membership renewal rate worldwide and an even higher rate in the United States (92.5%) in its most recent quarter. Currently, Costco charges $60 for a Gold Star membership and $120 for an Executive membership. Executive members have been rising in importance for the company.
Dow Jones futures were little changed ahead of the Federal Reserve's two-day meeting and big earnings from Amazon and Apple this week.
While its investments in building materials manufacturer Louisiana Pacific and investment banking firm Jefferies Financial Group were familiar buys in the Berkshire investing mold and constituted relatively small investments, the third new portfolio addition was eye-catching. Berkshire Hathaway purchased 60 million shares of Taiwan Semiconductor Manufacturing Company (NYSE: TSM), which was worth approximately $4.1 billion at the time of publication of the investment conglomerate's most recent 13-F filing in November. The big buy made TSMC Berkshire Hathaway's 10th-largest overall stock holding and marked the first time that it had held a position in a pure-play semiconductor company since it exited a small position in Intel back in 2012.
While every market advisor will tell you never to try to ‘time’ the market, timing is still important for success. Investors need to buy into low prices, and to do that, they need to know when prices are low. This doesn’t necessarily mean low in absolute dollar terms, but low relative to a stock’s recent past performance. In recognizing that lower price range, investors can turn to Wall Street’s pros for help. The analysts have been busy lately, picking out stocks that are in their lower price r
Spotify reported fourth quarter financial results before the bell on Tuesday. Here's what to know.
Yahoo Finance Live’s Brian Sozzi breaks down a JPMorgan analyst’s Underweight rating and $120 price target on Tesla stock.
In this article, we will take a look at the 15 most undervalued value stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Value Stocks To Buy According To Hedge Funds. Investors began to pile into value stocks in 2022 as financial markets wavered amid rising […]
Yahoo Finance Live’s Dave Briggs looks ahead to Snap’s earnings report due out tomorrow afternoon.
In this article, we will take a look at the 15 undervalued defensive stocks for 2023. You can skip this part and go to 5 Undervalued Defensive Stocks For 2023. Investors flocked to defensive stocks in 2022 amid recession fears and massive losses in the growth stocks space. Defensive stocks are favored by investors during […]
The Street’s experts build their reputations by the quality of their market and stock assessments, and they’re coming out in force now to give their interpretations of the strong start we’ve seen in 2023. The S&P 500 index is up 5%, while the teach-heavy Nasdaq has gained nearly 10%. It’s a welcome reprieve from last year’s downward trends; the question is, will it hold? Watching the situation from investment firm Evercore ISI, strategist Julian Emanuel has his doubts. He’s recommending that inv
Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock.
(Bloomberg) — Alibaba Group Holding Ltd.’s biggest selloff in three months is underscoring investor concern that China’s consumer recovery may fail to meet lofty expectations.Most Read from BloombergWall Street Is Losing Out to Amateur Buyers in the Housing SlumpTrump Sues Journalist Bob Woodward for Releasing Interview RecordingsSony Slashes PlayStation VR2 Headset Output After Pre-Orders DisappointThe 'Big Shift' That's Finally Causing Rents to FallAdani Rout Hits $68 Billion as Fight With Hi
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Chevron's giant $36.5 billion 2022 profit turned heads — including at the White House. But plenty of S&P 500 companies will make even more than the oil giant.

source